```json
{
"content": [
{
"type": "paragraph",
"content": "The Psoriatic Arthritis (PsA) Drugs market addresses a chronic autoimmune condition affecting joints and skin, with therapies focusing on biologics, biosimilars, and traditional DMARDs. As global prevalence rises and awareness expands, the PsA Drugs market size is projected to exceed $6.5 billion in 2026, reflecting robust momentum from pipeline innovations and tailored treatment approaches. This market forecast underscores a CAGR of ~9.2% from 2026โ2033, driven by macro forces including digital health integration, regulatory incentives for orphan drug designations, and a growing emphasis on patient-centric care models."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Biologics", "Non-Biologics", "Biosimilars"],
"periods": ["2020", "2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38], // Biologics
[8, 8, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9], // Non-Biologics
[3, 4, 5, 6, 7, 8, 9, 11, 13, 15, 17, 19, 21, 23] // Biosimilars
]
}
},
{
"type": "paragraph",
"content": "Key industry expansion dynamics include technological shifts toward personalized medicine and regulatory tailwinds in North America, the largest market segment, which hosts 45% of global R&D activity. Meanwhile, Asia-Pacific emerges as the fastest-growing region, fueled by expanding healthcare access and a rising aging population. Competitive intensity is escalating as biosimilar entrants challenge biologics dominance, while supply-chain resilience and digital diagnostics are reshaping treatment pathways for stakeholders."
}
]
}
```
